Evidence map›Paper›PMID 36607476›Full record

ArticleInternational journal of clinical oncology2023

Reciprocal expression of the immune response genes CXCR3 and IFI44L as module hubs are associated with patient survivals in primary central nervous system lymphoma.

Yasuo Takashima, Momoko Hamano, Kengo Yoshii, Azusa Hayano, Junya Fukai, Yasuo Iwadate, Koji Kajiwara, Hiroaki Hondoh, Ryuya Yamanaka

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. UnravelingFrontiers in oncology · 2024
    Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Yasuo TakashimaLaboratory of Molecular Target Therapy for Cancer,, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-Cho, Kawaramachi-Hirokoji, Kamigyo-Ku, Kyoto, 602-8566, Japan.ORCID http://orcid.org/0000-0001-8876-6673
Momoko Hamano *Department of Bioscience and Bioinformatics, Faculty of Computer Science and Systems Engineering, Kyushu Institute of Technology, Iizuka, Fukuoka, Japan.
Kengo Yoshii *Department of Mathematics and Statistics in Medical Sciences, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Azusa HayanoLaboratory of Molecular Target Therapy for Cancer,, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-Cho, Kawaramachi-Hirokoji, Kamigyo-Ku, Kyoto, 602-8566, Japan.
Junya FukaiDepartment of Neurological Surgery, Wakayama Medical University School of Medicine, Wakayama, Japan.
Yasuo IwadateDepartment of Neurosurgery, Graduate School of Medical Sciences, Chiba University, Chiba, Japan.
Koji KajiwaraDepartment of Neurosurgery, Graduate School of Medical Sciences, Yamaguchi University, Ube, Yamaguchi, Japan.
Hiroaki HondohDepartment of Neurosurgery, Toyama Prefectural Central Hospital, Toyama, Japan.
Ryuya YamanakaLaboratory of Molecular Target Therapy for Cancer,, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-Cho, Kawaramachi-Hirokoji, Kamigyo-Ku, Kyoto, 602-8566, Japan. ryaman@koto.kpu-m.ac.jp.
Kyoto Prefectural University of Medicine · JPChiba University · JPKyushu Institute of Technology · JPToyama Prefectural Central Hospital · JPWakayama Medical University · JPYamaguchi University · JP

Funding

MEXT KAKENHI 21H03045
6 · The paper itself

Abstract

purposeHere, we investigated expression modules reflecting the reciprocal expression of the cancer microenvironment and immune response-related genes associated with poor prognosis in primary central nervous system lymphoma (PCNSL).

methodsWeighted gene coexpression network analysis revealed representative modules, including neurogenesis, immune response, anti-virus, microenvironment, gene expression and translation, extracellular matrix, morphogenesis, and cell adhesion in the transcriptome data of 31 PCNSL samples.

resultsGene expression networks were also reflected by protein-protein interaction networks. In particular, some of the hub genes were highly expressed in patients with PCNSL with prognoses as follows: AQP4, SLC1A3, GFAP, CXCL9, CXCL10, GBP2, IFI6, OAS2, IFIT3, DCN, LRP1, and LUM with good prognosis; and STAT1, IFITM3, GZMB, ISG15, LY6E, TGFB1, PLAUR, MMP4, FTH1, PLAU, CSF3R, FGR, POSTN, CCR7, TAS1R3, small ribosomal subunit genes, and collagen type 1/3/4/6 genes with poor prognosis. Furthermore, prognosis prediction formulae were constructed using the Cox proportional-hazards regression model, which demonstrated that the IP-10 receptor gene CXCR3 and type I interferon-induced protein gene IFI44L could predict patient survival in PCNSL.

conclusionThese results indicate that the differential expression and balance of immune response and microenvironment genes may be required for PCNSL tumor growth or prognosis prediction, which would help understanding the mechanism of tumorigenesis and potential therapeutic targets in PCNSL.

Indexed as

Central Nervous System NeoplasmsLymphomaCentral Nervous SystemHumansImmunityMembrane ProteinsPrognosisProportional Hazards ModelsReceptors, CXCR3RNA-Binding ProteinsTumor MicroenvironmentCXCR3 protein, humanIFITM3 protein, humanMembrane ProteinsReceptors, CXCR3RNA-Binding ProteinsImmune responseMicroenvironmentMorphogenesisNeurogenesisPrimary central nervous system lymphomaWeighted correlation network analysis

Identifiers

PMID36607476
OpenAlexW4313645981

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.